<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40013141</article-id><article-id pub-id-type="pmc">PMC11860879</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1542326</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Xiong</surname><given-names>Zixuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2918053"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Huang</surname><given-names>Yichun</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Shulong</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1040503"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Huang</surname><given-names>Xuqun</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Haiyuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1122310"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>School of Basic Medicine, Health Science Center, Yangtze University</institution>, <addr-line>Jingzhou</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Oncology, The First Affiliated Hospital of Kunming Medical University</institution>, <addr-line>Kunming</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Department of Pathology, Songzi People&#x02019;s Hospital</institution>, <addr-line>Jingzhou</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Department of Medical Oncology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University</institution>, <addr-line>Huangshi</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Fernando Torres And&#x000f3;n, Institute of Biomedical Research of A Coru&#x000f1;a (INIBIC), Spain</p></fn><fn fn-type="edited-by"><p>Reviewed by: Silvia Campello, University of Rome Tor Vergata, Italy</p><p>Dwijendra K. Gupta, Allahabad University, India</p></fn><corresp id="fn001">*Correspondence: Haiyuan Zhang, <email xlink:href="mailto:hyzhang_88@163.com">hyzhang_88@163.com</email>; Xuqun Huang, <email xlink:href="mailto:huangxuqun74@outlook.com">huangxuqun74@outlook.com</email>
</corresp><fn fn-type="equal" id="fn003"><p>&#x02020;These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1542326</elocation-id><history><date date-type="received"><day>09</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Xiong, Huang, Cao, Huang and Zhang</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Xiong, Huang, Cao, Huang and Zhang</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Advanced ovarian cancer (AOC) is prone to recurrence, which can be attributed to drug resistance. Drug resistance may be related to the tumor microenvironment (TME), including the immune and non-immune TME. In the immune TME, the immune effector cells such as dendritic cells (DCs), M1-like tumor-associated macrophages (M1-TAMs), and T cells are inhibited. In contrast, immunosuppressive cells such as M2-like tumor-associated macrophages (M2-TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs) are activated. These changes make it difficult to produce immune effects and affect the efficacy of chemo-immunotherapy. In the non-immune TME, mechanisms such as apoptosis inhibition, DNA damage response (DDR), and epithelial-mesenchymal transition (EMT) can promote tumor growth, metastasis, and drug resistance. Despite the challenges posed by the TME in the treatment of AOC, the unique biological advantages of nanoparticles (NPs) make it possible to regulate the TME. NPs can stimulate the immune responses of M1-TAMs, DCs, and T cells while reducing the infiltration of immune suppressive cells such as M2-TAMs and Tregs, thereby regulating the AOC immune TME. In addition, NPs can regulate the non-immune TME by reducing apoptosis in AOC cells, inhibiting homologous recombination (HR) repair, reversing EMT, and achieving the effect of reversing drug resistance. In summary, the application of NPs provides some new venues for clinical treatment in AOC.</p></abstract><kwd-group><kwd>advanced ovarian cancer (AOC)</kwd><kwd>tumor microenvironment (TME)</kwd><kwd>chemo-immunotherapy</kwd><kwd>drug resistance</kwd><kwd>nanotechnology</kwd></kwd-group><funding-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Our work was supported by the Research Project of The Central Hospital of Huangshi (Grant No. ZX2023M03), the Plan Project of Jingzhou Science and Technology (Grant No.2024HD201), the Key Project of Joint Funds of Hubei Health and Family Planning Commission (Grant No. WJ2018H174).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="2"/><equation-count count="0"/><ref-count count="69"/><page-count count="16"/><word-count count="8328"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Cancer Immunity and Immunotherapy</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Ovarian cancer (OC) is the gynecological tumor with the highest mortality rate (<xref rid="B1" ref-type="bibr">1</xref>). Due to its unclear early symptoms and lack of effective screening methods, most patients with OC are already in the advanced stage when seeking medical treatment (<xref rid="B2" ref-type="bibr">2</xref>). Advanced ovarian cancer (AOC) often spreads to adjacent or distant tissues and organs through implantation, invasion, metastasis, etc., seriously affecting the life quality of patients and reducing their survival time. Tumor cell reduction surgery combined with chemo-immunotherapy is currently a commonly used treatment for AOC (<xref rid="B3" ref-type="bibr">3</xref>), but the therapeutic effect is not ideal. In recent years, with the continuous updates of chemotherapy drugs and immunotherapy regimens, the clinical treatment efficacy of AOC has greatly improved. However, patients with AOC are prone to developing drug resistance to chemotherapy and immunotherapy, which is another clinical challenge (<xref rid="B4" ref-type="bibr">4</xref>). Therefore, exploring the drug resistance mechanism of AOC cells and improving the drug sensitivity of tumor cells are urgent challenges that need to be addressed in clinical practice.</p><p>Related studies have shown that the tumor microenvironment (TME) may be closely related to the development of AOC and the regulation of drug resistance (<xref rid="B5" ref-type="bibr">5</xref>). The TME refers to the internal and external environment in which tumor cells are closely related to tumor occurrence and metastasis. It not only includes the function and metabolism of the tumor tissue, but also is related to the internal environment of the tumor cells themselves. TME includes immune cells, mesenchymal cells, and extracellular matrix (<xref rid="B6" ref-type="bibr">6</xref>). The TME is a complex and dynamic ecological environment in AOC. It can be regulated by the immune TME such as immunosuppression, immune evasion, or non-immune TME such as apoptosis inhibition, DNA damage response (DDR), and epithelial-mesenchymal transition (EMT). These factors affect the occurrence and development of AOC and lead to drug resistance in ovarian cancer cells (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Therefore, it may enhance the sensitivity of tumor cells to chemo-immunotherapy and improve the clinical treatment efficacy of patients with AOC by exploring the mechanism of TME in AOC and screening key intervention targets.</p><p>Nanotechnology is a technology that studies the properties and applications of materials with structural sizes ranging from 1 nanometer to 100 nanometers, its ultimate goal is to directly construct products with specific functions using atoms or molecules (<xref rid="B9" ref-type="bibr">9</xref>). Many reports have shown that the application of nanotechnology can effectively regulate the TME, thereby enhancing its therapeutic effect on malignant tumors (<xref rid="B10" ref-type="bibr">10</xref>). For example, constructed NPs can target drug delivery by enhancing the permeability and retention (EPR) effect, significantly increasing drug accumulation at tumor sites, reducing toxicity to normal tissues, and remodeling the TME in breast cancer (<xref rid="B11" ref-type="bibr">11</xref>). In the treatment of lung cancer, poly (lactic-co-glycolic acid) copolymer (PLGA) NPs carry targeted drugs, which can prolong the duration of action of the drugs in the body and improve the efficacy of drugs by controlling the release rate of drugs. In addition, effective tumor suppression is due to the direct elimination of lung cancer cells and TAM, thereby regulating the TME (<xref rid="B12" ref-type="bibr">12</xref>). The application of NPs not only improves the therapeutic effect, but also reduces side effects, providing strong support for personalized precision medicine. We have reviewed the mechanisms of the TME and introduced NPs that can regulate the TME in AOC, as well as describing their application value and prospects.</p></sec><sec id="s2"><label>2</label><title>The pitfalls of AOC: the immune TME</title><p>The immune TME of AOC is an important component of TME, which is a complex ecosystem composed of tumor cells, immune cells, extracellular matrix (ECM), and various cytokines. There are various immune active cells (ICCs) and immune suppressive cells in the immune TME. Among them, ICCs include dendritic cells (DCs), T cells, B cells, natural killer cells (NK cells), and tumor associated macrophages (TAMs) (<xref rid="B13" ref-type="bibr">13</xref>). ICCs are responsible for clearing foreign substances and playing an effector role in immune responses. Immunosuppressive cells, including regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs). Immunosuppressive cells mainly exert their immune negative regulatory effects by inhibiting the function of ICC. The immune cells in the immune TME are regulated by various factors, such as the immune checkpoint protein programmed cell death ligand 1 (PD-L1), which can recognize T cells to indicate programmed cell death 1 (PD-1) receptors and mediate immune escape effects. The characteristics of immune TME in AOC are the high concentration of immunosuppressive cells and low concentration of ICC, which greatly reduces the immune ability of ovarian cancer patients. This not only leads to resistance of ovarian cancer cells to chemo-immunotherapy drugs, but also promotes invasion and metastasis of ovarian cancer cells. Therefore, elucidating the mechanism of immune TME can provide a new treatment approach for reversing drug resistance in ovarian cancer cells and improving the efficacy of chemo-immunotherapy.</p><sec id="s2_1"><label>2.1</label><title>Immune checkpoint: PD-L1 inhibits activation of T cells in the immune TME</title><p>PD-L1 is a ligand-protein mainly expressed on the surface of tumor cells and can bind to PD-1. PD-1 is expressed on the surface of T cells and is an important immunosuppressive molecule. PD-L1 in the TME recognizes and binds to PD-1 on the surface of T cells, which can exert functions such as inhibiting T cell proliferation, promoting T cell apoptosis, and reducing cytokine secretion (<xref rid="B14" ref-type="bibr">14</xref>). The activated PD-1/PD-L1 signaling pathway can mediate tumor cell evasion of T cell immune response. The transcription factor signaling transducer and activator of transcription 3 (STAT3) plays important regulatory roles in the PD-1/PD-L1 signaling pathway (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>), and STAT3 activation is closely related to the regulation of the JAK2/STAT3 signaling pathway. When the cytokine interleukin-6 (IL-6) binds to the tumor cell receptor gp130, it can activate downstream JAK2 protein, which can phosphorylate STAT3 protein. Phosphorylated STAT3 protein forms a dimer and subsequently transfers to the nucleus. The STAT3 protein dimer in the nucleus promotes the transcription and expression of PD-L1 by binding to the promoter region of the PD-L1 gene (<xref rid="B15" ref-type="bibr">15</xref>). When the JAK2/STAT3 signaling pathway activates PD-L1, it binds to PD-1 expressed on the surface of T cells, activates the PD-1/PD-L1 signaling pathway, inhibits T cell function, and mediates immunosuppression.</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Signaling pathways in the immune TME in AOC. The JAK2/STAT3 signaling pathway upregulates PD-L1 expression and enhances T cell immune escape. WNT/&#x003b2;-catenin signaling pathway increases VEGF-A expression and activates the M2-TAMs. NF-&#x003ba;B signaling pathway and CD39/CD73 activate MDSCs by promoting the secretion of cytokines CXCL2 and adenosine, respectively. MDSCs release TGF-&#x003b2; to inhibit NK cells. Tregs are activated by NF-&#x003ba;B signaling pathway and PI3K/Akt signaling pathway, all of which inhibit DCs and CTL.</p></caption><graphic xlink:href="fimmu-16-1542326-g001" position="float"/></fig></sec><sec id="s2_2"><label>2.2</label><title>The activity of DCs in the immune TME is inhibited</title><p>DCs are antigen-presenting cells (APCs) that play a crucial role in initiating and regulating immune responses. However, the immune TME of AOC not only has a small number of DCs, but also easily leads to functional disorders, which may be related to tumor metabolic regulation. It induces the production of reactive oxygen species (ROS) in response to the high metabolic demands caused by the abnormal proliferation of AOC cells, thereby triggering lipid peroxidation in tumor cells (<xref rid="B16" ref-type="bibr">16</xref>). The lipid peroxidation of ovarian cancer cell membranes produces products such as 4-hydroxynonenal (4-HNE) (<xref rid="B17" ref-type="bibr">17</xref>). 4-HNE and ROS can act as signaling molecules to transmit oxidative stress signals to DCs, disrupting the endoplasmic reticulum redox homeostasis of DCs, leading to protein misfolding and endoplasmic reticulum stress (ERs) in DCs. The occurrence of ERs can lead to an increase in the synthesis of X-box binding protein 1 (XBP1). XBP1 can regulate lipid metabolism, promote abnormal accumulation of lipids, and lead to fatty acid oxidation (<xref rid="B18" ref-type="bibr">18</xref>). The above process may downregulate the ability of DCs to secrete pro-inflammatory cytokines (such as IL-12) and affect the function of DCs.</p></sec><sec id="s2_3"><label>2.3</label><title>The role and activation of TAMs in the immune TME</title><p>According to their activation status and function, TAMs are divided into different subgroups, namely M1-like tumor-associated macrophages (M1-TAMs) and M2-like tumor-associated macrophages (M2-TAMs) (<xref rid="B19" ref-type="bibr">19</xref>). M1-TAMs can release inflammatory substances such as IL-1 and exert anti-tumor effects by promoting inflammatory responses (<xref rid="B20" ref-type="bibr">20</xref>). In contrast, M2-TAM secretes anti-inflammatory cytokines such as IL-10 and transforming growth factor &#x003b2; (TGF-&#x003b2;), which are involved in inhibiting immunity and promoting tumor growth (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). However, M1-TAMs are rarely distributed in AOC immune TME, while M2-TAMs are attracted to chemokines regulated by the TME, such as VEGF-A which induced by the WNT/&#x003b2;-catenin signaling pathway. When the WNT ligand binds to the Frizzled receptor on the cell surface, it activates the WNT/&#x003b2;-catenin signaling pathway. In the presence of WNT signaling, degradation of &#x003b2;-catenin is inhibited, allowing it to accumulate in the cytoplasm and transfer to the nucleus. The &#x003b2;-catenin in the nucleus binds to the TCF/LEF family transcription factor and initiates the transcription and expression of the VEGF-A gene. VEGF-A attracts M2-TAMs to the tumor site, resulting in immunosuppressive TME (<xref rid="B23" ref-type="bibr">23</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>).</p></sec><sec id="s2_4"><label>2.4</label><title>The activation and function of MDSCs in the immune TME</title><p>MDSCs are a type of immune suppressive cells derived from bone marrow, which are precursors of DCs, macrophages, and granulocytes (<xref rid="B24" ref-type="bibr">24</xref>). They have the ability to significantly suppress immune cell responses and exhibit significant heterogeneity. The activation of MDSCs is influenced by a variety of factors, such as the chemokine CXC motif chemokine ligand 2 (CXCL2) and the metabolite adenosine (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>). CXCL2 is regulated by the NF-&#x003ba;B signaling pathway (<xref rid="B25" ref-type="bibr">25</xref>). The NF-&#x003ba;B signaling pathway is a complex and intricate system, with key components including receptors, receptor proximal signaling adaptor proteins, the inhibitor protein family of NF-&#x003ba;B dimers (I&#x003ba;B), I&#x003ba;B kinase (IKK) complexes, and NF-&#x003ba;B dimers. When the NF-&#x003ba;B signaling pathway is activated, IKK plays a key role, and its activation leads to phosphorylation and ubiquitination of I&#x003ba;B protein, which in turn leads to its degradation. With the degradation of I&#x003ba;B protein, NF-&#x003ba;B dimer is released and activated. These activated NF-&#x003ba;B dimers are transferred to the nucleus and can act as transcription factors to bind to the promoter region of the CXCL2 gene, promoting its transcription and expression. CXCL2 activates and recruits MDSCs into the immune TME by binding to CXCR2 on the surface of MDSCs. In addition, the metabolite adenosine is also involved in the activation of MDSCs. Adenosine is produced by ATP molecules through a series of enzymatic reactions. Adenosine activates MDSCs by specifically binding to A2A receptors on the surface of MDSCs, inhibiting immune responses in TME and promoting tumor immune escape (<xref rid="B26" ref-type="bibr">26</xref>).</p></sec><sec id="s2_5"><label>2.5</label><title>The recruitment of Tregs in the immune TME</title><p>Tregs are subpopulations of T cells that are immunosuppressive. When Tregs accumulate in the immune TME, they transmit inhibitory signals by expressing cytotoxic T lymphocyte-associated protein-4 (CTLA-4), thereby preventing DCs from presenting tumor antigens to CTLs, prompting immunosuppression. The activation of Tregs in the immune TME of AOC is influenced by the TNF-TNFR2 axis (<xref rid="B27" ref-type="bibr">27</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>). TNF recognizes and binds to TNFR2 on the surface of tumor cells, and activated TNFR2 acts on and activates downstream receptor-interacting protein kinase 1 (RIPK1). Activated RIPK1 is rapidly ubiquitinated and degraded by the TRAF2-cIAP1-cIAP2 complex, thereby maintaining the signal homeostasis of the TNF-TNFR2 axis. Activated RIPK1 promotes the activation of IKK complexes by phosphorylating IKK subunits. The activation of IKK can lead to the degradation of IKB, resulting in the activation of NF-&#x003ba;B dimer and its entry into the nucleus, regulating the expression of IL-2. And cytokine IL-2 can activate Treg by binding to IL-2R on the surface of Treg. In addition, activated TNFR2 can also act on and activate downstream erythroblast transformation-specific tyrosine kinase (ETK), thereby activating the PI3K/AKT signaling pathway mediated by ETK. ETK activates PI3K to convert phosphatidylinositol diphosphate (PIP2) into phosphatidylinositol triphosphate (PIP3), and then activates downstream protein AKT. The PI3K/Akt pathway mediates phosphorylation activation of STAT5 through a cascade effect. Phosphorylated STAT5 enters the nucleus and recognizes and binds to the regulatory sequence of TGF-&#x003b2; gene, enhancing the expression and secretion of TGF-&#x003b2;. TGF-&#x003b2; in the TME can stimulate Tregs to secrete immunosuppressive cytokines, further exerting their immunosuppressive function.</p></sec></sec><sec id="s3"><label>3</label><title>The pitfalls of AOC tumor: the non-immune TME</title><p>There are some components in the TME of AOC that are not directly related to immune regulation, but can regulate tumor cell growth, metastasis, and drug resistance. We classify it as the non-immune TME.</p><sec id="s3_1"><label>3.1</label><title>Non-immune TME regulates proliferation and migration of AOC cells</title><p>In non-immune TME, tumor cell growth is mainly regulated by the PI3K/AKT/mTOR signaling pathway, RAS/RAF/MAPK signaling pathway, and WNT/&#x003b2;-catenin signaling pathway (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>). Abnormal activation of the PI3K/AKT/mTOR pathway can inhibit tumor cell apoptosis, promote tumor cell growth and proliferation, facilitate tumor cell angiogenesis and metabolism, participate in tumor cell invasion and metastasis (<xref rid="B28" ref-type="bibr">28</xref>). The activation of the PI3K/AKT/mTOR pathway is closely related to the regulation of receptor tyrosine kinase (RTK). Growth factors in the non-immune TME recognize and bind to RTK on the surface of tumor cells. Activated RTK exerts protein kinase activity, recruits PI3K, and converts PIP2 into PIP3, thereby activating downstream AKT. Activated AKT regulates protein and lipid synthesis by phosphorylating and activating mTORC1, promoting abnormal proliferation of tumor cells. The RAS/RAF/MAPK signaling pathway is another key pathway for non-immune TME regulation of AOC occurrence and development. This pathway is initiated by the binding and activation of epidermal growth factor (EGF) to the cell surface receptor EGFR. After receptor activation, son of sevenless (Sos) are recruited to the plasma membrane. The function of Sos is to convert the Ras on the inner side of the cell membrane from GDP-Ras to GTP-Ras, thereby activating Ras. Activate Ras recruitment and activate RAF, leading to RAF phosphorylation. Phosphorylated RAF subsequently activates downstream MEK, which in turn activates ERK. Activated ERK is transferred to the nucleus and stimulates phosphorylation of various transcription factors, including myeloid leukemia factor 1 (Mcl-1), cellular oncogene Jun (c-Jun), and cellular oncogene fos (c-fos). These transcription factors promote cell proliferation, survival, and cell cycle progression (<xref rid="B29" ref-type="bibr">29</xref>). The WNT/&#x003b2;-catenin signaling pathway also plays an important role in the occurrence and development of ovarian cancer. When the WNT ligand recognizes and binds to Frizzled receptors on the cell surface, it facilitates the formation of a WNT protein-Frizzled receptor-LRP5/6 trimer. This trimeric complex activates the intracellular Dvl protein, destabilizing the APC-Axin-GSK-3&#x003b2; degradation complex. As a result, &#x003b2;-catenin phosphorylation and subsequent degradation are inhibited, leading to an increase of &#x003b2;-catenin in the cytoplasm, which then translocates into the nucleus. The &#x003b2;-catenin entering the nucleus binds to the TCF/LEF transcription factor family, initiating the transcription and expression of downstream target genes such as MEF2D. MEF2D can enhance the expression of the VEGF gene in tumor cells, thereby promoting angiogenesis and inducing abnormal proliferation of tumor cells (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). In summary, the non-immune TME can regulate the proliferation and metastasis of ovarian cancer cells by activating the three signaling pathways mentioned above.</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>Multiple signaling pathways in the non-immune TME in AOC. ATP7A/B causes the efflux of platinum drugs. PI3K/AKT/mTOR signaling pathway promotes tumor proliferation, induces EMT and enhances tumor metastasis, inhibits apoptosis and protects against autophagy in AOC. RAS/RAF/MAPK signaling pathway promotes proliferation in tumor. Wnt/&#x003b2;-catenin signaling pathway stimulates cell proliferation and abnormal glycolysis in AOC. BRCA cause DNA damage repair.</p></caption><graphic xlink:href="fimmu-16-1542326-g002" position="float"/></fig><p>EMT is one of the key processes in the development of ovarian cancer and refers to the transformation of epithelial cells into mesenchymal cells (<xref rid="B32" ref-type="bibr">32</xref>), giving tumor cells the ability to migrate, invade, and promote tumor metastasis and recurrence. It has been reported that the induction of EMT is associated with the TGF-&#x003b2; signaling pathway (<xref rid="B33" ref-type="bibr">33</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>), which is divided into Smad-dependent and Smad-independent pathways (<xref rid="B34" ref-type="bibr">34</xref>). In the Smad-dependent pathway, TGF-&#x003b2; binds to its receptor and activates Smad proteins, leading to the translocation of Smad complexes into the nucleus to regulate the downregulation of E-cadherin expression and upregulation of mesenchymal markers such as N-cadherin and Vimentin in ovarian cancer epithelial cells. Furthermore, within the Smad-independent pathway, TGF-&#x003b2; can activate additional signaling pathways such as MAPK and PI3K/AKT, which collectively regulate the expression of transcription factors including Snail, Twist, and ZEB1. This regulation leads to the inhibition of E-cadherin expression and facilitates the process of EMT. Non-immune TME induces EMT in AOC cells and promotes tumor cell migration.</p></sec><sec id="s3_2"><label>3.2</label><title>Drug resistance induced by the non-immune TME</title><p>The occurrence of drug resistance in AOC is a complex process influenced by multiple factors, including the regulation of the immune TME mentioned previously. Currently, some studies have suggested that the non-immune TME can also regulate drug resistance in AOC cells. We have summarized some non-immune TME related factors that lead to drug resistance in AOC, including abnormal glycolysis, inhibition of tumor cell apoptosis, reduction of drug accumulation, and DDR.</p><sec id="s3_2_1"><label>3.2.1</label><title>Non-immune TME in AOC regulates abnormal glycolysis in tumor cells</title><p>Cancer cells preferentially produce energy through glycolysis even when oxygen is abundant. This process, known as the Warburg effect, enables the rapid production of ATP and metabolic intermediates, supporting the rapid proliferation and survival of cancer cells (<xref rid="B35" ref-type="bibr">35</xref>). Some miRNAs in the non-immune TME of AOC play an important role in the Warburg effect, such as miR-1180. MiR-1180 inhibits the translation of SFRP1 mRNA by targeting its 3&#x02019;UTR, thereby reducing extracellular SFRP1 protein levels. As a negative regulator of the WNT/&#x003b2;-catenin pathway, SFRP1 typically inhibits the pathway by binding to WNT ligands or Frizzled receptors (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>). Consequently, the reduction of SFRP1 leads to overactivation of the WNT/&#x003b2;-catenin signaling pathway and upregulates the expression of the key glycolytic enzyme PDK1, which promotes glycolysis by inhibiting pyruvate dehydrogenase (PDH) activity (<xref rid="B36" ref-type="bibr">36</xref>). The abnormal upregulation of glycolysis may be one of the reasons why non-immune TME regulates drug resistance in AOC cells.</p></sec><sec id="s3_2_2"><label>3.2.2</label><title>Non-immune TME in AOC regulates apoptosis inhibition in tumor cells</title><p>Apoptosis is a programmed cell death that is regulated by intracellular gene expression and signaling pathways, and is an important mechanism for the body to eliminate damaged, infected, or tumor cells. However, in order to promote their survival and proliferation, tumor cells inhibit apoptosis through various mechanisms, such as the regulation of aberrant miRNAs in the non-immune TME of AOC (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>). The increased formation of miRNAs, such as miR-214, miR-93 and miR-223, inhibits tumor suppressor gene PTEN (<xref rid="B37" ref-type="bibr">37</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>), activates PI3K/AKT signaling pathway, stimulates phosphorylation of downstream glycogen synthase kinase 3b (GSK3b) and p70 ribosomal protein S6 kinase (p70S6K), inhibits the activity of apoptosis-related proteins such as BAD (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Therefore, the inhibition of apoptosis induced by the non-immune TME of AOC can lead to drug resistance in tumor cells.</p></sec><sec id="s3_2_3"><label>3.2.3</label><title>Non-immune TME in AOC can regulate the decrease of drug accumulation in tumor cells</title><p>Platinum-based drugs are first-line chemotherapy drugs for AOC adjuvant therapy, but due to their long usage cycle, ovarian cancer cells are prone to develop drug resistance to platinum-based drugs. The molecular mechanism of drug resistance in ovarian cancer cells may be related to copper efflux transporters, including copper transporter 1 (CTR1), ATP7A, and ATP7B (<xref rid="B41" ref-type="bibr">41</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>). CTR1, as the main transporter protein of platinum drugs, has been shown to affect the intracellular content of platinum drugs at its expression level. It can reduce the expression of CTR1 protein in cancer cells due to inflammatory factors produced in the non-immune TME of AOC, leading to a decrease in the effective content of platinum-based chemotherapeutic agents within the cells and inducing drug resistance (<xref rid="B42" ref-type="bibr">42</xref>). In addition, ATP7A and ATP7B are also involved in regulating the transport of platinum-based drugs within tumor cells (<xref rid="B43" ref-type="bibr">43</xref>). Given that tumor cells are metabolized through aerobic fermentation, ROS present in the non-immune TME of AOC upregulates the expression of ATP7A and ATP7B by activating the Nrf2 signaling pathway. ATP7A can isolate platinum-based drugs into cell vesicles, reducing their contact with tumor cell DNA. ATP7B promotes the transport of platinum-based drugs to the extracellular space. In summary, copper flux transporters generate drug resistance by reducing the intracellular levels of chemotherapy drugs in tumor cells.</p></sec><sec id="s3_2_4"><label>3.2.4</label><title>Non-immune TME in AOC regulates DDR in tumor cells</title><p>DDR is one of the fundamental physiological mechanisms in biology, which is a highly conserved mechanism for cells to resist DNA damage induced by external and internal factors. But ovarian cancer cells can repair the damage to the tumor cell genome caused by platinum-based chemotherapy drugs by inducing excessive activation of DDR. ROS produced by aerobic fermentation of ovarian cancer cells can activate ATM and ATR in tumor cells, leading to phosphorylation of downstream Chk2 kinase. Chk2 kinase can activate downstream BRCA proteins, thereby regulating the DDR effect and leading to resistance of ovarian cancer cells to platinum-based drugs (<xref rid="B44" ref-type="bibr">44</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>).</p></sec></sec></sec><sec id="s4"><label>4</label><title>The strategy for pitfall in AOC: application of nanotechnology in the regulation of the immune TME</title><p>Although the presence of an immune TME poses a significant challenge in the treatment of AOC, the inherent targeting, multifunctionality, and pharmacokinetic advantages of NPs allow precise regulation of the immune TME. The role of nanotechnology in AOC chemo-immunotherapy has attracted widespread attention. We have summarized and reviewed the reported applications and research, listing various NP designs, including their compositions and corresponding signaling pathways (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>).</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Application of NPs in the immune TME of AOC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Categories</th><th valign="middle" align="center" rowspan="1" colspan="1">NPs</th><th valign="middle" align="center" rowspan="1" colspan="1">Material</th><th valign="middle" align="center" rowspan="1" colspan="1">Medicine</th><th valign="middle" align="center" rowspan="1" colspan="1">Function</th><th valign="middle" align="center" rowspan="1" colspan="1">Pathway</th><th valign="middle" align="center" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">TAMs</td><td valign="middle" align="center" rowspan="1" colspan="1">UBR5-silencing nanoparticles</td><td valign="middle" align="center" rowspan="1" colspan="1">MSV</td><td valign="middle" align="center" rowspan="1" colspan="1">Ubr5 siRNA polyplex</td><td valign="middle" align="center" rowspan="1" colspan="1">Disrupted paracrine regulation of TAMs infiltration</td><td valign="middle" align="center" rowspan="1" colspan="1">Wnt/&#x003b2;-catenin</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B45" ref-type="bibr">45</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TAMs</td><td valign="middle" align="center" rowspan="1" colspan="1">VSSP</td><td valign="middle" align="center" rowspan="1" colspan="1">NAcGM3 and OMV</td><td valign="middle" align="center" rowspan="1" colspan="1">VSSP</td><td valign="middle" align="center" rowspan="1" colspan="1">Polarization; Altered surface markers, cytokine secretion</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B46" ref-type="bibr">46</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TAMs</td><td valign="middle" align="center" rowspan="1" colspan="1">RSQ-loaded liposomes</td><td valign="middle" align="center" rowspan="1" colspan="1">Liposomes</td><td valign="middle" align="center" rowspan="1" colspan="1">RSQ</td><td valign="middle" align="center" rowspan="1" colspan="1">TAM activation; Induced Th1 response</td><td valign="middle" align="center" rowspan="1" colspan="1">NF-&#x003ba;B</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B47" ref-type="bibr">47</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TAMs</td><td valign="middle" align="center" rowspan="1" colspan="1">HA-PEI-miR- 125b</td><td valign="middle" align="center" rowspan="1" colspan="1">HA-PEI</td><td valign="middle" align="center" rowspan="1" colspan="1">miR-125b</td><td valign="middle" align="center" rowspan="1" colspan="1">Repolarized TAMs; Reduced VEGF</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B48" ref-type="bibr">48</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TAMs</td><td valign="middle" align="center" rowspan="1" colspan="1">miR497/TP-<break/>HENPs</td><td valign="middle" align="center" rowspan="1" colspan="1">Exosomes, liposomes</td><td valign="middle" align="center" rowspan="1" colspan="1">TP, miR497</td><td valign="middle" align="center" rowspan="1" colspan="1">Polarization; Increased TNF-&#x003b1;</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B49" ref-type="bibr">49</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">DCs</td><td valign="middle" align="center" rowspan="1" colspan="1">KT-NE</td><td valign="middle" align="center" rowspan="1" colspan="1">nanoemulsion</td><td valign="middle" align="center" rowspan="1" colspan="1">KIRA6-loaded &#x003b1;-Tocopherol</td><td valign="middle" align="center" rowspan="1" colspan="1">Reduced lipid abundance in TIDCs; Restored DCs-dependent immunity</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B50" ref-type="bibr">50</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">DCs</td><td valign="middle" align="center" rowspan="1" colspan="1">FCM-NPs</td><td valign="middle" align="center" rowspan="1" colspan="1">PLGA</td><td valign="middle" align="center" rowspan="1" colspan="1">CpG-ODN and FCs Membrane</td><td valign="middle" align="center" rowspan="1" colspan="1">Activated CTLs, IFN-&#x003b3; and so on</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B51" ref-type="bibr">51</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">DCs</td><td valign="middle" align="center" rowspan="1" colspan="1">IRO@FA NPs</td><td valign="middle" align="center" rowspan="1" colspan="1">PLGA</td><td valign="middle" align="center" rowspan="1" colspan="1">PFH cores surrounded by IR780</td><td valign="middle" align="center" rowspan="1" colspan="1">Increased mature DCs and T cells</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B52" ref-type="bibr">52</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">DCs</td><td valign="middle" align="center" rowspan="1" colspan="1">Fe3O4-ICG@ IRM</td><td valign="middle" align="center" rowspan="1" colspan="1">Fe3O4 NPs</td><td valign="middle" align="center" rowspan="1" colspan="1">IRM</td><td valign="middle" align="center" rowspan="1" colspan="1">Increased tumor antigens</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B53" ref-type="bibr">53</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">DCs</td><td valign="middle" align="center" rowspan="1" colspan="1">CbP/siPD-L1@Dig</td><td valign="middle" align="center" rowspan="1" colspan="1">CuS NPs</td><td valign="middle" align="center" rowspan="1" colspan="1">Dig and siPD-L1</td><td valign="middle" align="center" rowspan="1" colspan="1">Apoptosis; Immunogenicity; Reduced PD-L1</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B54" ref-type="bibr">54</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T cells</td><td valign="middle" align="center" rowspan="1" colspan="1">TNFR2 antibody NPs</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">TNFR2 antibodies</td><td valign="middle" align="center" rowspan="1" colspan="1">Reduced TNFR2</td><td valign="middle" align="center" rowspan="1" colspan="1">NF-&#x003ba;B;PI3K/Akt</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B27" ref-type="bibr">27</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T cells</td><td valign="middle" align="center" rowspan="1" colspan="1">PbAE-mRNA polyplexes</td><td valign="middle" align="center" rowspan="1" colspan="1">PbAE</td><td valign="middle" align="center" rowspan="1" colspan="1">IVT mRNA</td><td valign="middle" align="center" rowspan="1" colspan="1">Triggered CD3 clustering; Activated T cells</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B55" ref-type="bibr">55</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T cells</td><td valign="middle" align="center" rowspan="1" colspan="1">Exo-miR-155-5p</td><td valign="middle" align="center" rowspan="1" colspan="1">Exosome</td><td valign="middle" align="center" rowspan="1" colspan="1">miR-155-5p</td><td valign="middle" align="center" rowspan="1" colspan="1">Downregulated PD-L1 and activated CD8+ T cell function</td><td valign="middle" align="center" rowspan="1" colspan="1">miR-155-5p/PD-L1</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B56" ref-type="bibr">56</xref>)</td></tr></tbody></table></table-wrap><sec id="s4_1"><label>4.1</label><title>Regulation of TAMs in the immune TME of AOC</title><p>In the immune TME of AOC, M2-TAMs have tumor-promoting properties and infiltrate abundantly, but M1-TAMs with anti-tumor properties are rarely distributed. Currently, many molecular drugs, such as TLR agonists or miRNAs, can be developed to promote TAM polarization. However, owing to factors such as low bioavailability, poor targeting, and instability <italic>in vivo</italic>, these drugs often fail to achieve the expected effects <italic>in vivo</italic>. However, nanotechnology can be used to convert these drugs into NPs and improve their targeting and utilization, thereby achieving the polarization of TAMs and improving the immune TME of AOC (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3A</bold>
</xref>).</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>Applications of NPs to reverse the immune TME in AOC. <bold>(A)</bold> Application of NPs targeting TAMs. (a) Ubr5-silencing NPs inhibit the WNT/&#x003b2;-catenin signaling pathway to stimulate M2-TAMs activation. (b) VSSP, RSQ-loaded liposomes, HA-PEI-miR-125b and miR497/TP-HENPs promote TAMs polarization. <bold>(B)</bold> Application of NPs targeting DCs. (a) KT-NE can restore DCs to produce antigen presentation. (b) FCM-NPs are used as a synthetic DCs that acts like normal DCs. (c) IRO@FA NPs, Fe3O4-ICG@IRM and CbP/siPD-L1@Dig exert the ICD effect and activate the function of DCs. <bold>(C)</bold> NP applications targeting T cells. (a) TNFR2 antibody NPs inhibit the NF-&#x003ba;B signaling pathway and PI3K/Akt signal pathway to suppress Tregs activity. (b) BiTE can promote the recognition of T cells and tumor cells. (c) miR-155-5p down-regulate PD-L1 and promote T cells activity.</p></caption><graphic xlink:href="fimmu-16-1542326-g003" position="float"/></fig><sec id="s4_1_1"><label>4.1.1</label><title>NPs terminate the recruitment of M2-TAMs by regulating the immune TME in AOC</title><p>As mentioned earlier, activation of the WNT/&#x003b2;-catenin signaling pathway upregulates VEGF-A, mediating the activation and infiltration of M2-TAMs. Therefore, inhibition of the WNT/&#x003b2;-catenin pathway may reduce the infiltration of M2-TAM in the immune TME. Song et&#x000a0;al. (<xref rid="B45" ref-type="bibr">45</xref>) found that the ubiquitin protein ligase E3 component n-recognin 5 (UBR5), a ubiquitin ligase homologous to the E6AP C-terminal (HECT) domain, can maintain &#x003b2;-catenin activation and upregulate key chemokines and cytokines to promote the recruitment and activation of M2-TAMs. Constructing NPs loaded with UBR5 siRNA can block the WNT/&#x003b2;-catenin signaling pathway and downregulate the VEGF-A gene by targeting and silencing UBR5 expression, thereby reducing the recruitment of M2-TAMs.</p></sec><sec id="s4_1_2"><label>4.1.2</label><title>NPs repolarize TAMs by regulating the immune TME in AOC</title><p>The phenotypic state of TAMs is highly dynamic, allowing them to respond to various factors in the immune TME and switch between M2 and M1 phenotypes, a process known as polarization. Currently, many molecular targeted drugs for TAM polarization have been developed, such as TLR agonists. TLR agonists can bind to TLRs on the surface of TAMs, activate the TLR signaling pathway, induce the expression of M1 markers including CD86, iNOS, and MHC-II in TAMs, and reduce the expression of M2 markers including CD206, CD163, and Arg-1, thereby promoting the transformation of TAMs from M2 phenotype to M1 phenotype. Recently, Khan et&#x000a0;al. (<xref rid="B46" ref-type="bibr">46</xref>) developed an NPs composed of GM3 ganglioside (NAcGM3) containing N-acetylneuraminic acid and Neisseria meningitidis outer membrane vesicles (OMV) (VSSP) assembled through hydrophobic interactions, which can act as TLR agonists to activate the transformation of M2-TAM to M1-TAM in the immune TME. In their report, the polysaccharide structure of NAcGM3 can be recognized by TLR-2, while the OMV component containing lipopolysaccharide (LPS) activates TLR-4, allowing VSSP to act as TLR-2/4 agonists. VSSPs converted M2-TAMs to M1-TAMs by downregulating the expression of M2-TAM marker CD206, and increasing the secretion of pro-inflammatory cytokines such as TNF-&#x003b1; and IL-1&#x003b2;, reversing immune suppressive cell function and enhancing immune activity in the immune TME. Kang et&#x000a0;al. (<xref rid="B47" ref-type="bibr">47</xref>) prepared resiquimod (RSQ) into specific NPs and precisely delivered them into tumor cells. RSQ is a TLR-7/8 agonist with immune stimulatory ability, which can promote the conversion of M2-TAM to M1-TAM, thereby improving the immune TME and enhancing anti-tumor immune response.</p><p>Parayath et&#x000a0;al. (<xref rid="B48" ref-type="bibr">48</xref>) found that some miRNAs affect the TAM phenotype, with miR-125b having the highest repolarization efficiency. Therefore, they encapsulated miR-125b with hyaluronic acid- poly(ethyleneimine) (HA-PEI) NPs that specifically target TAMs to prepare HA-PEI-miR-125b NPs, thereby inducing phenotypic transformation of TAMs. In ID8 OC model mice administered HA-PEI-miR-125b NPs by intraperitoneal injection, the experimental group showed a significant decrease in M2-TAMs and a significant increase in M1-TAMs. These results demonstrate that the nanotechnology-mediated delivery of miR-125b can effectively repolarize TAMs in immune TME and be used in combination with chemotherapy drugs to enhance anti-tumor effects, providing a new idea for the treatment of ovarian cancer.</p></sec></sec><sec id="s4_2"><label>4.2</label><title>Regulation of DCs in the immune TME of AOC</title><p>Although DCs have been shown to play a central role in tumor-specific immune responses, the infiltration of DCs in the immune TME of AOC is relatively insufficient. To enhance the function of DCs, a variety of strategies can be adopted: first, to improve the antigen presentation capacity of under functioning DCs; second, prepare artificial DCs to enhance the immune response; finally, immunogenic cell death (ICD) is used to activate the function of DCs (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3B</bold>
</xref>).</p><sec id="s4_2_1"><label>4.2.1</label><title>NPs improve ineffective DCs by regulating the immune TME in AOC</title><p>As described above, lipid accumulation and ERs regulated by the immune TME in AOC affect the function of DCs. Restoring the functionality of DCs is a topic worth studying. Lu et&#x000a0;al. designed a KT-NE nanoemulsion to target the lipid accumulation caused by abnormal ER and oxidative stress in the TME (<xref rid="B50" ref-type="bibr">50</xref>). The main components of KT-NE are KIRA6 and &#x003b1;-tocopherol. KIRA6 is an advanced small molecule IRE1&#x003b1; kinase and RNase inhibitor that reduces the synthesis of FAs through XBP1. &#x003b1;-Tocopherol relieves oxidative stress, blocks the generation of 4-HNE, and is a powerful ROS scavenger. In summary, the construction of NPs can synergistically inhibit the ROS-triggered lipid peroxidation, repair the function of damaged DCs in the immune TME, enhance the efficiency of antigen presentation, activate T cell-mediated immune responses, and improve the effect of chemo-immunotherapy.</p></sec><sec id="s4_2_2"><label>4.2.2</label><title>Artificial NPs replace DCs in the immune TME</title><p>Even without effective DC penetration, we can use biomimetic nanomaterials to manufacture artificial DC NPs. Zhang et&#x000a0;al. (<xref rid="B51" ref-type="bibr">51</xref>) prepared FCM-NPs, artificial biomimetic nanoDCs that can exhibit antigen presentation and immunostimulatory effects in the immune TME. The preparation of FCM-NPs involves first fusing ovarian cancer cells with DCs in mouse bone marrow, using the polyethylene glycol (PEG) method to generate fused cells (FC), preserving the immunogenicity of tumor cells and the antigen presentation function of DCs, and extracting the cell membrane of FC. Then select PLGA-NPs encapsulate the extracted fusion cell membrane and immune modulator CpG-ODN, and finally make FCM-NPs. Therefore, FCM-NPs have the antigen presentation ability of DCs, increases the expression levels of co-stimulatory molecules such as CD80 and CD86, and stimulates immature T lymphocytes to produce a large number of tumor-specific cytotoxic CD8+T lymphocytes. According to the experimental results, FCM-NPs exhibit strong immune activation and significant anti-tumor effects in both <italic>in vitro</italic> and <italic>in vivo</italic> experiments, and have good biocompatibility. This shows that constructing NPs to simulate the antigen presentation and immune activation functions of DCs can effectively enhance the activation of CTLs, thereby reshaping the immune TME, and improving the effect of chemo-immunotherapy.</p></sec><sec id="s4_2_3"><label>4.2.3</label><title>NPs activate DCs by inducing ICD in immune TME of AOC</title><p>When tumor cells die under external stimuli, the process by which they can transition from non-immunogenic to immunogenic and mediate the body&#x02019;s anti-tumor immune response is called ICD. When tumor cells develop into ICD, they produce a series of signaling molecules called damage-associated molecular patterns (DAMPs), which mainly include calreticulin (CRT), high mobility protein 1 (HMGB1), ATP molecules, and heat shock proteins (HSP70 and HSP90). These molecules can bind to pattern recognition receptors (PRRs) on the surface of DCs, thereby attracting DCs to migrate to the tumor site and enhancing the recognition and attack of immune cells on the tumor. Ling et&#x000a0;al. (<xref rid="B54" ref-type="bibr">54</xref>) designed a nanoscale coordination polymer particles (NCP) with a core encapsulating the chemotherapeutic drugs carboplatin and siPD-L1 and a shell incorporating digoxin(Dig), called CbP/siPD-L1@Dig. Once these NCPs are taken up and ruptured intracellularly, Dig, an ICD inducer, induces immunogenicity, carboplatin induces apoptosis, and siPD-L1 can knock down PD-L1 expression to reduce immunosuppression. The results showed that cells treated with CbP/siPD-L1@Dig significantly increased the release of DAMPs such as ATP and HMGB1, activated DCs, promoted their maturation and antigen presentation ability, and regulated the immune TME to facilitate chemo-immunotherapy. Similarly, Zheng et&#x000a0;al. (<xref rid="B52" ref-type="bibr">52</xref>) designed a sonodynamic therapy (SDT) nanoplatform to induce ICD in ovarian cancer cells. They encapsulated the photosensitizer IR780 with PLGA and attached FA for improved targeting, then added perfluorohexane (PFH), an oxygen-carrying material, and named it IRO@FA NPs. Experiments showed that the DAMPs changed significantly and the expression levels of IL-6 were significantly elevated in ovarian cancer cells treated with IRO@FA NPs, suggesting that ICDs are induced in tumor cells and activate DCs, initiating an immune response. Therefore, the construction of NPs to induce ICD can activate the function of DCs in the immune TME, promote antigen presentation, and improve the body&#x02019;s immune response, thereby improving the effect of chemo-immunotherapy.</p></sec></sec><sec id="s4_3"><label>4.3</label><title>Regulation of T cells in the non-immune TME in AOC</title><p>T cells play a crucial role in enhancing the immune response of patients. There are often three ways to activate the positive regulatory role of T cells in AOC immune TME: one is to terminate the recruitment of Tregs, the other is to increase the infiltration of effector T cells, and the third is to increase the role of exosomes (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3C</bold>
</xref>).</p><sec id="s4_3_1"><label>4.3.1</label><title>NPs terminate Treg recruitment by regulating the immune TME in AOC</title><p>As previously described, the NF-&#x003ba;B or PI3K/Akt signaling pathways in the immune TME of AOC can promote Treg infiltration by regulating relevant cytokines. If these aforementioned pathways are blocked, Treg activation in TME may be downregulated. Al-Hatamleh et&#x000a0;al. (<xref rid="B27" ref-type="bibr">27</xref>) proposed the following hypothesis. They suggest that blocking the TNF-TNFR2 axis by NPs containing TNFR2 antibodies can affect the activation of NF-&#x003ba;B or PI3K/Akt signaling pathways, downregulating Treg-associated cytokines such as TGF-&#x003b2; and IL-2, thereby reducing the activation and distribution of Tregs.</p></sec><sec id="s4_3_2"><label>4.3.2</label><title>NPs increase infiltration of effector T cells by regulating the immune TME in AOC</title><p>Owing to the lack of T cell infiltration in the immune TME of ovarian cancer, recruiting T cells from other locations to achieve chemo-immunotherapy could be a promising strategy, and bispecific T cell engagers (BiTEs) can achieve it. BiTE is an artificial antibody with two antigen-binding sites, one binding to the CD3 molecule on the T cell and the other binding to a specific antigen on the tumor cell, thereby bringing the T cells and the tumor cells together and activating the killing function of the T cells (<xref rid="B57" ref-type="bibr">57</xref>). However, the imprecise targeting and non-tumor toxicity of BiTE in TME make it less effective against solid tumors. Hao et&#x000a0;al. (<xref rid="B55" ref-type="bibr">55</xref>) designed targeted nanocarriers that can deliver mRNA encoding BiTE, which is transcribed <italic>in vitro</italic>, to bone marrow cells that can target immune TME. The result indicated that when encountering BiTEs-bound tumor cells, T cells can be activated, secrete the pro-inflammatory cytokine IFN-&#x003b3;, and thus effectively kill ovarian cancer cells.</p></sec><sec id="s4_3_3"><label>4.3.3</label><title>Exosomes reduce immune checkpoint suppression by regulating the immune TME in AOC</title><p>Exosomes are membrane vacuoles released into the extracellular matrix after the fusion of multivesicular bodies (MVBs) with the cell membrane, which are important mediators of intercellular substances and signal transduction. They affect the biological functions of recipient cells by carrying and transmitting bioactive molecules, such as exosome delivery of miR-155-5p inhibiting the inactivation of T cells and the infiltration of TAMs by targeting PD-L1. However, the ROS produced by the indefinite proliferation of AOC cells can inhibit the expression of miR-155-5p in exosomes. Li et&#x000a0;al. (<xref rid="B56" ref-type="bibr">56</xref>) found that miR-155-5p levels in tumor cell exosomes increased after neutralizing ROS by using N-acetylcysteine (NAC). This treatment not only increases the proportion of CD8+ T cells and decreases T cell apoptosis, but also decreases macrophage migration capacity and tumor spheroid infiltration. This study reveals the important role of ROS and exosomal miR-155-5p in the immune TME of AOC, providing a theoretical basis for the development of new therapeutic strategies in the future.</p></sec></sec></sec><sec id="s5"><label>5</label><title>The strategy for pitfall in AOC: application of nanotechnology in the regulation of non-immune TME</title><p>Although non-immune TME presents many challenges for the treatment of AOC, various NPs offer promising strategies for addressing these challenges. We have summarized and reviewed the reported applications and research, listing various NP designs, including their compositions and corresponding signaling pathways (<xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>).</p><table-wrap position="float" id="T2"><label>Table&#x000a0;2</label><caption><p>Application of NPs in the non-immune TME of AOC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Categories</th><th valign="middle" align="center" rowspan="1" colspan="1">NPs</th><th valign="middle" align="center" rowspan="1" colspan="1">Material</th><th valign="middle" align="center" rowspan="1" colspan="1">Medicine</th><th valign="middle" align="center" rowspan="1" colspan="1">Function</th><th valign="middle" align="center" rowspan="1" colspan="1">Targeted point/Pathway</th><th valign="middle" align="center" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">Metastasis</td><td valign="middle" align="center" rowspan="1" colspan="1">GNP</td><td valign="middle" align="center" rowspan="1" colspan="1">Gold NPs</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">Reversing EMT</td><td valign="middle" align="center" rowspan="1" colspan="1">MAPK; PI3K/AKT</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B58" ref-type="bibr">58</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Drug resistance</td><td valign="middle" align="center" rowspan="1" colspan="1">R-Se@MEF2D-siRNA</td><td valign="middle" align="center" rowspan="1" colspan="1">SeNPs</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">Apoptosis; mitochondrial dysfunction</td><td valign="middle" align="center" rowspan="1" colspan="1">WNT/MEF2D</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B31" ref-type="bibr">31</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Drug resistance</td><td valign="middle" align="center" rowspan="1" colspan="1">Sal-AgNPs</td><td valign="middle" align="center" rowspan="1" colspan="1">AgNPs</td><td valign="middle" align="center" rowspan="1" colspan="1">salinomycin</td><td valign="middle" align="center" rowspan="1" colspan="1">Apoptosis; autophagy</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B59" ref-type="bibr">59</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Drug resistance</td><td valign="middle" align="center" rowspan="1" colspan="1">miR497/TP-HENPs</td><td valign="middle" align="center" rowspan="1" colspan="1">Exosomes,liposomes</td><td valign="middle" align="center" rowspan="1" colspan="1">TP; miR497</td><td valign="middle" align="center" rowspan="1" colspan="1">Increased ROS; apoptosis</td><td valign="middle" align="center" rowspan="1" colspan="1">PI3K/AKT/mTOR</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B49" ref-type="bibr">49</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Drug resistance</td><td valign="middle" align="center" rowspan="1" colspan="1">MEnZn-CuO NPs</td><td valign="middle" align="center" rowspan="1" colspan="1">Zn-CuO NPs</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">Inhibited DNA repair</td><td valign="middle" align="center" rowspan="1" colspan="1">BRCA</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B60" ref-type="bibr">60</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Drug resistance</td><td valign="middle" align="center" rowspan="1" colspan="1">RGD-CaPO/DOX</td><td valign="middle" align="center" rowspan="1" colspan="1">RGD</td><td valign="middle" align="center" rowspan="1" colspan="1">CaPO/DOX</td><td valign="middle" align="center" rowspan="1" colspan="1">ER stress; calcium overload; mitochondrial dysfunction</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B61" ref-type="bibr">61</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Drug resistance</td><td valign="middle" align="center" rowspan="1" colspan="1">IDEM-DOXO</td><td valign="middle" align="center" rowspan="1" colspan="1">DOXO</td><td valign="middle" align="center" rowspan="1" colspan="1">IDEM</td><td valign="middle" align="center" rowspan="1" colspan="1">Apoptosis</td><td valign="middle" align="center" rowspan="1" colspan="1">\</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B62" ref-type="bibr">62</xref>)</td></tr></tbody></table></table-wrap><sec id="s5_1"><label>5.1</label><title>NPs improve the sensitivity of AOC therapy by regulating the non-immune TME</title><p>Multiple mechanisms underlie drug resistance caused by non-immune TME in AOC. Many reports have indicated that the application of nanotechnology can effectively regulate non-immune TME, reverse drug resistance and improve the treatment sensitivity. We have summarized some examples of the modulation of the non-immune TME by constructing specific NPs, including the promotion of apoptosis, inhibition of proliferation, prevention of DDR, and reversal of EMT.</p><sec id="s5_1_1"><label>5.1.1</label><title>NPs promote apoptosis by regulating the non-immune TME in AOC</title><p>Apoptosis inhibition is one of the important factors leading to treatment insensitivity and drug resistance in ovarian cancer. In recent years, more and more studies have begun to focus on the promotion of apoptosis through the modulation of apoptosis-related signaling pathways to overcome drug resistance in the non-immune TME. Li et&#x000a0;al. (<xref rid="B49" ref-type="bibr">49</xref>) designed NPs targeting inhibition of the PI3K/AKT/mTOR pathway to promote apoptosis in AOC cells. They fused cRGD-modified liposomes with CD47-expressing exosomes from TME to form bio-inspired hybrid NPs, and encapsulated triptolide (TP) and miR497 to prepare miR497/TP-HEPs. CD44-expressing exosomes can bind to SIRP&#x003b1; on the surface of tumor cells without being affected by the tumor clearance system, TP and miR497 inhibit the mTOR signaling pathway, reduce cell metabolism to provide energy and nutrients for tumor cells, and make ovarian cancer cells more sensitive to cisplatin treatment. The experimental results show that the PI3K/AKT/mTOR signaling pathway is inhibited by miR497/TP-HENPs-treated ovarian cancer cells, which reduces the expression of anti-apoptotic proteins, such as Bcl-2 and Bcl-XL, promotes apoptosis and overcomes cell drug resistance. In addition, the preparation of NPs that can activate the caspase-mediated apoptotic pathway can also play an equal role in TME. For example, Zhang et&#x000a0;al. (<xref rid="B59" ref-type="bibr">59</xref>) synthesized silver nanoparticles (AgNPs) with cytotoxicity using a novel bacterium named Bacillus clausii and selected salinomycin (Sal) with cancer stem cell destruction function. The combination of Sal and AgNPs was found to activate caspase-3 and caspase-9, inducing caspase cascade pathways and ultimately leading to apoptosis. Therefore, apoptosis can be induced by NPs modulation of apoptosis-related pathways, thereby overcoming drug resistance in AOC (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4A</bold>
</xref>, a).</p><fig position="float" id="f4"><label>Figure&#x000a0;4</label><caption><p>Applications of NPs to reverse the non-immune TME in AOC. NPs destroy tumors by promoting apoptosis, inhibiting proliferation, disrupting HR repair and reversing EMT. <bold>(A)(a)</bold>(a) miR497/TP-HENPs can promote apoptosis by inhibiting PI3K/AKT/mTOR signaling pathway. Sal-AgNPs and IDEM-DOXO promote AOC cell apoptosis by activating Caspase-3-depended signaling pathways. (b) RGD-CaPO/DOX NPs and R-Se@MEF2D-siRNA induce apoptosis directly via increasing ROS preparation, mitochondrial damage and ER stress. <bold>(B)</bold> R-Se@MEF2D-siRNA also inhibits cells proliferation by blocking the WNT/&#x003b2;-catenin signaling pathway. <bold>(C)</bold> MEnZn-CuO NPs decreases the expression of HR repairing markers associated with DNA repair mechanisms. <bold>(D)</bold> GNPs reverse EMT by inactivates PI3K/AKT signaling pathway and MAPK signaling pathway.</p></caption><graphic xlink:href="fimmu-16-1542326-g004" position="float"/></fig><p>There are many ways to induce apoptosis, but most current research still focuses on exploring through a single pathway. Although this single-mechanism approach is helpful for understanding the role of specific pathways, its therapeutic effect may be limited by factors such as the complexity of the TME and the drug resistance of tumor cells. Because of this, the construction of a platform for multi-mechanism induction of apoptosis with the help of NPs may provide a more efficient and targeted solution. For example, Qiu et&#x000a0;al. (<xref rid="B61" ref-type="bibr">61</xref>) devised an amorphous calcium phosphate (CaPO) modified with doxorubicin (DOX)-loaded Arg-Gly-Asp (RGD) (RGD-CaPO/DOX) to induce apoptosis. When absorbed by cells, the NPs release calcium ions and DOX, which is a chemotherapeutic agent that can increase ROS levels to induce ERs. The high concentrations of ROS disrupt the function of calcium channels and calcium pumps on the cell membrane, resulting in increased calcium ion inflow and exacerbating intracellular calcium overload. Their synergistic effect exacerbates mitochondrial dysfunction, which ultimately leads to apoptosis. Furthermore, animal experiments demonstrated that RGD-CaPO/DOX exhibits significant tumor suppression <italic>in vivo</italic>. Tumor cells in mice treated with RGD-CaPO/DOX showed more severe apoptosis than those treated with DOX alone, reflecting the effectiveness and safety of RGD-CaPO/DOX NPs (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4A</bold>
</xref>, b).</p></sec><sec id="s5_1_2"><label>5.1.2</label><title>NPs inhibit the proliferation by regulating the non-immune TME in AOC</title><p>As previously described, MEF2D is an important transcription factor in the WNT/&#x003b2;-catenin signaling pathway, leading to tumor proliferation by upregulating the expression of VEGF. Wang et&#x000a0;al. (<xref rid="B31" ref-type="bibr">31</xref>) attempted to synthesize MEF2D-siRNA-based NPs to achieve effective silencing of MEF2D and thereby inhibit tumor proliferation. They selected selenium nanoparticles (SeNPs) that facilitate drug or gene delivery, installed charged RGDfC peptides on the surface of NPs to enhance targeting, and finally successfully prepared R-Se@MEF2D-siRNA NPs. The results showed that the MEF2D gene in ovarian cancer cells treated with R-Se@MEF2D-siRNA was inhibited, blocking the WNT/&#x003b2;-catenin pathway, thereby reducing VEGF secretion in the non-immune TME, reducing vascularization, thereby reducing nutrient and oxygen supply to tumors, and inhibiting AOC cell proliferation (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4B</bold>
</xref>). Therefore, R-Se@MEF2D-siRNA exhibits excellent anti-tumor effects <italic>in vivo</italic> by inhibiting tumor cell proliferation.</p></sec><sec id="s5_1_3"><label>5.1.3</label><title>NPs prevent DDR by regulating the non-immune TME in AOC</title><p>The DDR regulated by the non-immune TME seriously affects the sensitivity of AOC treatment (<xref rid="B63" ref-type="bibr">63</xref>). Yi et&#x000a0;al. (<xref rid="B60" ref-type="bibr">60</xref>) discovered that micelle-encapsulated zinc-doped copper oxide nanoparticles (MEnZn-CuO NPs) can reverse the resistance of ovarian cancer to the PARP inhibitor Olaparib by disrupting homologous recombination (HR) repair. The results showed that MEnZn-CuO NPs significantly reduced the expression of HR repair pathway-related genes (BRCA1, BRCA2, ATM, and RAD51) (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4C</bold>
</xref>). Further studies into the effects of MEnZn-CuO NPs have found that they can be used in combination with PARP inhibitors and have shown synergistic inhibition of ovarian cancer cell growth in both <italic>in vitro</italic> and <italic>in vivo</italic> experiments. Therefore, MEnZn-CuO NPs, as a novel nanocomposite, significantly enhance the sensitivity of ovarian cancer cells to the PARP inhibitor by destroying the HR repair ability and have potential application value in reversing drug resistance in the non-immune TME.</p></sec></sec><sec id="s5_2"><label>5.2</label><title>NPs reduce tumor metastasis by regulating the non-immune TME in AOC</title><p>As previously mentioned, the occurrence of EMT is closely related to the activation of the PI3K/AKT signaling pathway by factors, such as cytokines and growth factors secreted by cancer-associated fibroblast (CAF) and endothelial cell (EC) communication in the non-immune TME. Recently, Zhang et&#x000a0;al. (<xref rid="B58" ref-type="bibr">58</xref>) prepared 20 nm gold nanoparticles (GNPs) by citrate reduction and found that GNPs down-regulate the expression of key cytokines and growth factors that activate the PI3K/AKT signaling pathway by blocking multicellular communication in the non-immune TME (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4D</bold>
</xref>). This down-regulation inhibits the activation of the PI3K/AKT signaling pathway, thereby reversing the EMT process in AOC and reducing the migration and invasion ability of tumor cells. Therefore, the construction of NPs inhibits EMT-related pathways and reduces tumor cell metastasis in non-immune TME, providing a new idea for the treatment of AOC.</p></sec></sec><sec sec-type="conclusions" id="s6"><label>6</label><title>Conclusion</title><p>Nanotechnology is a science and technology based on many modern advanced scientific technologies, and it is a product of the combination of dynamic science and modern technology. The latest advances in nanotechnology have accelerated research on NPs construction, making it possible to develop complex drug delivery systems (<xref rid="B64" ref-type="bibr">64</xref>). It can enhance the specificity of the drug&#x02019;s action and reduce toxic side effects on normal organ tissues by integrating multiple drugs together and targeting specific locations in the body to construct NPs. Therefore, NPs have been widely used in the diagnosis and treatment of diseases, especially in the field of cancer. Ovarian cancer is a common malignant tumor in women, and multiple studies have shown that its high mortality and recurrence rates may be related to the regulation of TME. In the TME, tumor cells can alter and maintain their own survival and development conditions through autocrine and paracrine pathways, promoting tumor growth and progression. Whole body and local tissues can also utilize the TME to restrict and influence the occurrence and development of tumors through metabolic and functional changes. Therefore, the complex mechanisms regulated by TME may affect the effectiveness of its adjuvant therapy, and even lead to resistance to chemo-immunotherapy (<xref rid="B65" ref-type="bibr">65</xref>). In this review, we elucidate the molecular mechanisms and intervention strategies of TME in regulating the occurrence and development of AOC. In the immune TME, functional inhibition of immune effector cells such as T cells and DCs, as well as abnormal activation of immune suppressive cells such as M2-TAMs, MDSCs, and Tregs, may be closely related to ovarian cancer progression and tumor cell drug resistance. In addition, the non-immune TME regulates abnormal proliferation and migration of ovarian cancer cells, abnormal aerobic glycolysis, apoptosis inhibition, and DDR, leading to poor clinical chemo-immunotherapy efficacy and tumor cell resistance. Reversing drug resistance in ovarian cancer cells and avoiding the recurrence of ovarian cancer is currently a clinical challenge. Many studies have shown that we can construct NPs to activate immune effector cells or block immune suppressive cell activity by regulating TME, enhancing the body&#x02019;s immune capacity, may achieving clinical effects of reversing drug resistance in ovarian cancer cells and intervening in the development of ovarian cancer (<xref rid="B66" ref-type="bibr">66</xref>). We can also regulate the non-immune TME by constructing NPs, promote tumor cell apoptosis, disrupt HR repair, and intervene in the mechanism of EMT occurrence, thereby increasing the sensitivity of ovarian cancer cells to chemo-immunotherapy and intervening in the progression of ovarian cancer. In summary, utilizing nanotechnology to regulate TME may provide a novel therapeutic strategy and approach for AOC.</p></sec><sec id="s7"><label>7</label><title>Future perspective</title><p>The molecular mechanism of TME regulating AOC is still being continuously improved and updated. The application of nanotechnology will bring more hope and expectations in ovarian cancer TME for clinical treatment. PANoptosis is currently a hot topic in the field of cancer research. Although the molecular mechanism of PANoptosis is not yet perfect, utilizing non-immune TME to regulate the PANoptosis effect of ovarian cancer cells may provide additional insights and surprises for the treatment of AOC in the future. PANoptosis is a recently discovered form of cell death that involves the simultaneous activation of multiple cell death pathways, including apoptosis, necrosis, and pyroptosis (<xref rid="B67" ref-type="bibr">67</xref>). It has been confirmed that PANoptosis can regulate the occurrence and development of tumors, reversing the drug resistance of tumor cells to chemo-immunotherapy (<xref rid="B68" ref-type="bibr">68</xref>). Given that TME may protect ovarian cancer cells from the PANoptosis effect caused by chemo-immunotherapy, we may be able to utilize nanotechnology to construct NPs that regulate TME to enhance the PANoptosis effect of ovarian cancer cells, thereby introducing new targeted and personalized treatment options for AOC patients. Given that the TME can protect tumor cells from killing by PANoptosis, in the near future, we may be able to enhance the sensitivity of ovarian cancer cells to PANoptosis by constructing NPs loaded with regulating TME drugs, thereby introducing new targeted and personalized treatment protocols for patients with AOC.</p><p>Due to recurrence and metastasis of AOC, it may be the main research direction for utilizing nanotechnology to regulate the immune TME of ovarian cancer cells and improve clinical adjuvant therapy efficacy in the future. Recent studies have shown that T cells in TME exhibit terminal differentiation depletion under continuous tumor antigen stimulation, commonly referred to as exhausted T cells (Tex cells) (<xref rid="B69" ref-type="bibr">69</xref>). It can significantly reduce the self-renewal and effector molecule release ability of Tex cells for a large amount of lactate produced and released by tumor cell metabolism, forming immunosuppressive TME. However, reports have shown that monocarboxylate transporter 11 (MCT11) may be closely related to the absorption of lactate by Tex cells. If specific MCT11 inhibitors can be developed in the future, nanotechnology can be used to construct NPs loaded with MCT11 inhibitors to reverse the immunosuppressive TME of AOC, providing a new concept for adjuvant therapy of ovarian cancer.</p><p>The complexity of TME has always been a major obstacle to the clinical adjuvant therapy of AOC. It can provide scientific basis about the application of nanotechnology to regulate TME for the development of new treatment strategies, and promote the personalized and precise development of AOC treatment.</p></sec></body><back><ack><title>Acknowledgments</title><p>All authors of this manuscript apologize to researchers whose works were not cited in this review article due to space limitations.</p></ack><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>ZX: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. YH: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. SC: Funding acquisition, Project administration, Software, Writing &#x02013; review &#x00026; editing. XH: Funding acquisition, Project administration, Resources, Validation, Visualization, Writing &#x02013; original draft. HZ: Funding acquisition, Project administration, Resources, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="disclaimer" id="s13"><title>Author disclaimer</title><p>We declare that all authors agreed to publish the manuscript at this journal and followed the publication ethics.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herbert</surname><given-names>SL</given-names></name><name><surname>Fick</surname><given-names>A</given-names></name><name><surname>Heydarian</surname><given-names>M</given-names></name><name><surname>Metzger</surname><given-names>M</given-names></name><name><surname>W&#x000f6;ckel</surname><given-names>A</given-names></name><name><surname>Rudel</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Establishment of the SIS scaffold-based 3D model of human peritoneum for studying the dissemination of ovarian cancer</article-title>. <source>J Tissue Eng</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>20417314221088514</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1177/20417314221088514</pub-id>
<pub-id pub-id-type="pmid">35340423</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name></person-group>. <article-title>Metformin inhibits the proliferation and invasion of ovarian cancer cells by suppressing tripartite motif-containing 37-induced tumor necrosis factor receptor-associated factor 2 ubiquitination</article-title>. <source>Cancer Sci</source>. (<year>2022</year>) <volume>113</volume>:<page-range>3776&#x02013;86</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/cas.15524</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ledermann</surname><given-names>JA</given-names></name><name><surname>Raja</surname><given-names>FA</given-names></name><name><surname>Fotopoulou</surname><given-names>C</given-names></name><name><surname>Gonzalez-Martin</surname><given-names>A</given-names></name><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Sessa</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann oncology: Off J Eur Soc Med Oncol</source>. (<year>2013</year>) <volume>24 Suppl 6</volume>:<page-range>vi24&#x02013;32</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/annonc/mdt333</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Rankin</surname><given-names>GO</given-names></name><name><surname>Rojanasakul</surname><given-names>Y</given-names></name><name><surname>Tu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name></person-group>. <article-title>Theaflavin-3, 3&#x02019;-digallate inhibits ovarian cancer stem cells via suppressing Wnt/&#x003b2;-Catenin signaling pathway</article-title>. <source>J Funct foods</source>. (<year>2018</year>) <volume>50</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jff.2018.09.021</pub-id>
<pub-id pub-id-type="pmid">30984291</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Dou</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group>. <article-title>AXL: shapers of tumor progression and immunosuppressive microenvironments</article-title>. <source>Mol Cancer</source>. (<year>2025</year>) <volume>24</volume>:<elocation-id>11</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12943-024-02210-9</pub-id>
<pub-id pub-id-type="pmid">39799359</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Gou</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Nie</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Development of a seven-gene tumor immune microenvironment prognostic signature for high-risk grade III endometrial cancer</article-title>. <source>Mol Ther oncolytics</source>. (<year>2021</year>) <volume>22</volume>:<fpage>294</fpage>&#x02013;<lpage>306</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.omto.2021.07.002</pub-id>
<pub-id pub-id-type="pmid">34553020</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le Saux</surname><given-names>O</given-names></name><name><surname>Ray-Coquard</surname><given-names>I</given-names></name><name><surname>Labidi-Galy</surname><given-names>SI</given-names></name></person-group>. <article-title>Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer</article-title>. <source>Semin Cancer Biol</source>. (<year>2021</year>) <volume>77</volume>:<page-range>127&#x02013;43</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.semcancer.2020.08.017</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Etzerodt</surname><given-names>A</given-names></name><name><surname>Moulin</surname><given-names>M</given-names></name><name><surname>Doktor</surname><given-names>TK</given-names></name><name><surname>Delfini</surname><given-names>M</given-names></name><name><surname>Mossadegh-Keller</surname><given-names>N</given-names></name><name><surname>Bajenoff</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer</article-title>. <source>J Exp Med</source>. (<year>2020</year>) <volume>217</volume>:<fpage>e20191869</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1084/jem.20191869</pub-id>
<pub-id pub-id-type="pmid">31951251</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patra</surname><given-names>JK</given-names></name><name><surname>Das</surname><given-names>G</given-names></name><name><surname>Fraceto</surname><given-names>LF</given-names></name><name><surname>Campos</surname><given-names>EVR</given-names></name><name><surname>Rodriguez-Torres</surname><given-names>MDP</given-names></name><name><surname>Acosta-Torres</surname><given-names>LS</given-names></name><etal/></person-group>. <article-title>Nano based drug delivery systems: recent developments and future prospects</article-title>. <source>J nanobiotechnology</source>. (<year>2018</year>) <volume>16</volume>:<fpage>71</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12951-018-0392-8</pub-id>
<pub-id pub-id-type="pmid">30231877</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name></person-group>. <article-title>Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy</article-title>. <source>Advanced Sci (Weinheim Baden-Wurttemberg Germany)</source>. (<year>2022</year>) <volume>9</volume>:<fpage>e2103836</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/advs.202103836</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Cai</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Solomevich</surname><given-names>SO</given-names></name><etal/></person-group>. <article-title>Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer</article-title>. <source>Wiley Interdiscip Rev Nanomedicine nanobiotechnology</source>. (<year>2024</year>) <volume>16</volume>:<elocation-id>e1950</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/wnan.1950</pub-id>
<pub-id pub-id-type="pmid">38528388</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>HT</given-names></name><name><surname>Peng</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy</article-title>. <source>Advanced Sci (Weinheim Baden-Wurttemberg Germany)</source>. (<year>2022</year>) <volume>9</volume>:<elocation-id>e2202039</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/advs.202202039</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Significance of STAT3 in immune infiltration and drug response in cancer</article-title>. <source>Biomolecules</source>. (<year>2020</year>) <volume>10</volume>(<issue>6</issue>):<fpage>834</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/biom10060834</pub-id>
<pub-id pub-id-type="pmid">32486001</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance</article-title>. <source>Sci Adv</source>. (<year>2023</year>) <volume>9</volume>:<fpage>0</fpage>&#x02013;<lpage>0</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/sciadv.ade4186</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group>. <article-title>Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway</article-title>. <source>Clin Immunol (Orlando Fla.)</source>. (<year>2021</year>) <volume>227</volume>:<elocation-id>108728</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.clim.2021.108728</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Shrivastava</surname><given-names>SK</given-names></name><name><surname>Srivastava</surname><given-names>RK</given-names></name><name><surname>Shankar</surname><given-names>S</given-names></name></person-group>. <article-title>Chronic alcohol exposure induces hepatocyte damage by inducing oxidative stress, SATB2 and stem cell-like characteristics, and activating lipogenesis</article-title>. <source>J Cell Mol Med</source>. (<year>2022</year>) <volume>26</volume>:<page-range>2119&#x02013;31</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/jcmm.17235</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>F</given-names></name><name><surname>Ara</surname><given-names>H</given-names></name><name><surname>Bess</surname><given-names>E</given-names></name><name><surname>Shum</surname><given-names>A</given-names></name><name><surname>Bhattarai</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Rotenone-induced 4-HNE aggresome formation and degradation in HL-1 cardiomyocytes: role of autophagy flux</article-title>. <source>Int J Mol Sci</source>. (<year>2022</year>) <volume>23</volume>(<issue>9</issue>):<fpage>4675</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms23094675</pub-id>
<pub-id pub-id-type="pmid">35563066</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maj</surname><given-names>T</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name></person-group>. <article-title>Dendritic cells are stressed out in tumor</article-title>. <source>Cell Res</source>. (<year>2015</year>) <volume>25</volume>:<page-range>989&#x02013;90</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/cr.2015.93</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>Gao</given-names></name><name><surname>Qian-Han</surname><given-names>Xu</given-names></name><name><surname>Li-Na</surname><given-names>Ma</given-names></name><name><surname>Jing</surname><given-names>Luo</given-names></name><name><surname>Kahindo P.</surname><given-names>Muyayalo</given-names></name><name><surname>Li-Ling</surname><given-names>Wang</given-names></name><etal/></person-group>
<article-title>. Trophoblast-derived lactic acid orchestrates decidual macrophage differentiation via SRC/LDHA signaling in early pregnancy</article-title>. <source>Int J Biol Sci</source>. (<year>2022</year>) <volume>18</volume>:<fpage>599</fpage>&#x02013;<lpage>616</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7150/ijbs.67816</pub-id>
<pub-id pub-id-type="pmid">35002512</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>B</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name></person-group>. <article-title>Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials</article-title>. <source>Biomedicine pharmacotherapy = Biomedecine pharmacotherapie</source>. (<year>2024</year>) <volume>177</volume>:<elocation-id>116930</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.biopha.2024.116930</pub-id>
<pub-id pub-id-type="pmid">38878638</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toledo</surname><given-names>B</given-names></name><name><surname>Zhu Chen</surname><given-names>L</given-names></name><name><surname>Paniagua-Sancho</surname><given-names>M</given-names></name><name><surname>Marchal</surname><given-names>JA</given-names></name><name><surname>Per&#x000e1;n</surname><given-names>M</given-names></name><name><surname>Giovannetti</surname><given-names>E</given-names></name></person-group>. <article-title>Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy</article-title>. <source>J Hematol Oncol</source>. (<year>2024</year>) <volume>17</volume>:<fpage>44</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13045-024-01559-0</pub-id>
<pub-id pub-id-type="pmid">38863020</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yung</surname><given-names>MMH</given-names></name><name><surname>Ngan</surname><given-names>HYS</given-names></name><name><surname>Chan</surname><given-names>KKL</given-names></name><name><surname>Chan</surname><given-names>DW</given-names></name></person-group>. <article-title>The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression</article-title>. <source>Int J Mol Sci</source>. (<year>2021</year>) <volume>22</volume>:<elocation-id>6560</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms22126560</pub-id>
<pub-id pub-id-type="pmid">34207286</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raghavan</surname><given-names>S</given-names></name><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>YL</given-names></name><name><surname>Mehta</surname><given-names>G</given-names></name></person-group>. <article-title>Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and Malignant phenotypes in 3D engineered microenvironments</article-title>. <source>J immunotherapy Cancer</source>. (<year>2019</year>) <volume>7</volume>:<fpage>190</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s40425-019-0666-1</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Ou</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer</article-title>. <source>Signal transduction targeted Ther</source>. (<year>2021</year>) <volume>6</volume>:<fpage>362</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41392-021-00670-9</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Xiong</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Piezo1 promotes vibration-induced vascular smooth muscle injury by regulating the NF-&#x003ba;B/p65 axis</article-title>. <source>Commun Biol</source>. (<year>2025</year>) <volume>8</volume>:<fpage>96</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s42003-025-07524-y</pub-id>
<pub-id pub-id-type="pmid">39833492</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taki</surname><given-names>M</given-names></name><name><surname>Abiko</surname><given-names>K</given-names></name><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Hamanishi</surname><given-names>J</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Murakami</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation</article-title>. <source>Nat Commun</source>. (<year>2018</year>) <volume>9</volume>:<fpage>1685</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-018-03966-7</pub-id>
<pub-id pub-id-type="pmid">29703902</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Hatamleh</surname><given-names>MAI</given-names></name><name><surname>E A R</surname><given-names>ENS</given-names></name><name><surname>Boer</surname><given-names>JC</given-names></name><name><surname>Ferji</surname><given-names>K</given-names></name><name><surname>Six</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Synergistic effects of nanomedicine targeting TNFR2 and DNA demethylation inhibitor-an opportunity for cancer treatment</article-title>. <source>Cells</source>. (<year>2019</year>) <volume>9</volume>:<elocation-id>33</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/cells9010033</pub-id>
<pub-id pub-id-type="pmid">31877663</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Driva</surname><given-names>TS</given-names></name><name><surname>Schatz</surname><given-names>C</given-names></name><name><surname>Haybaeck</surname><given-names>J</given-names></name></person-group>. <article-title>Endometriosis-associated ovarian carcinomas: how PI3K/AKT/mTOR pathway affects their pathogenesis</article-title>. <source>Biomolecules</source>. (<year>2023</year>) <volume>13</volume>:<elocation-id>1253</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/biom13081253</pub-id>
<pub-id pub-id-type="pmid">37627318</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leng</surname><given-names>R</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group>. <article-title>NUF2 overexpression contributes to epithelial ovarian cancer progression via ERBB3-mediated PI3K-AKT and MAPK signaling axes</article-title>. <source>Front Oncol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>1057198</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fonc.2022.1057198</pub-id>
<pub-id pub-id-type="pmid">36620547</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Ponnusamy</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group>. <article-title>MEF2 signaling and human diseases</article-title>. <source>Oncotarget</source>. (<year>2017</year>) <volume>8</volume>:<page-range>112152&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.18632/oncotarget.22899</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Huo</surname><given-names>S</given-names></name><name><surname>Shou</surname><given-names>D</given-names></name><name><surname>Mei</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Silencing of MEF2D by siRNA loaded selenium nanoparticles for ovarian cancer therapy</article-title>. <source>Int J nanomedicine</source>. (<year>2020</year>) <volume>15</volume>:<page-range>9759&#x02013;70</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2147/IJN.S270441</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>YM</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>JX</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Inhibition of ZIP4 reverses epithelial-to-mesenchymal transition and enhances the radiosensitivity in human nasopharyngeal carcinoma cells</article-title>. <source>Cell Death Dis</source>. (<year>2019</year>) <volume>10</volume>:<fpage>588</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41419-019-1807-7</pub-id>
<pub-id pub-id-type="pmid">31383854</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>AD</given-names></name><name><surname>Zhang</surname><given-names>LP</given-names></name><name><surname>Zuo</surname><given-names>YX</given-names></name><name><surname>Jia</surname><given-names>YP</given-names></name></person-group>. <article-title>Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi</article-title>. <source>Chin J Hematol.</source> (<year>2019</year>) <volume>40</volume>:<page-range>52&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3760/cma.j.issn.0253-2727.2019.01.010</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Derynck</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>YE</given-names></name></person-group>. <article-title>Smad-dependent and Smad-independent pathways in TGF-beta family signalling</article-title>. <source>Nature</source>. (<year>2003</year>) <volume>425</volume>:<page-range>577&#x02013;84</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nature02006</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vaupel</surname><given-names>P</given-names></name><name><surname>Multhoff</surname><given-names>G</given-names></name></person-group>. <article-title>Revisiting the Warburg effect: historical dogma versus current understanding</article-title>. <source>J Physiol</source>. (<year>2021</year>) <volume>599</volume>:<page-range>1745&#x02013;57</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1113/JP278810</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gu</surname><given-names>ZW</given-names></name><name><surname>He</surname><given-names>YF</given-names></name><name><surname>Wang</surname><given-names>WJ</given-names></name><name><surname>Tian</surname><given-names>Q</given-names></name><name><surname>Di</surname><given-names>W</given-names></name></person-group>. <article-title>MiR-1180 from bone marrow-derived mesenchymal stem cells induces glycolysis and chemoresistance in ovarian cancer cells by upregulating the Wnt signaling pathway</article-title>. <source>J Zhejiang University. Science. B</source>. (<year>2019</year>) <volume>20</volume>:<page-range>219&#x02013;37</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1631/jzus.B1800190</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype</article-title>. <source>J Exp Clin Cancer research: CR</source>. (<year>2019</year>) <volume>38</volume>:<fpage>81</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13046-019-1095-1</pub-id>
<pub-id pub-id-type="pmid">30770776</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>JD</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN</article-title>. <source>Cancer Res</source>. (<year>2008</year>) <volume>68</volume>:<page-range>425&#x02013;33</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2488</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Xing</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>LY</given-names></name><name><surname>Xie</surname><given-names>SS</given-names></name><name><surname>Xiong</surname><given-names>WD</given-names></name></person-group>. <article-title>L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade</article-title>. <source>J B.U.ON.: Off J Balkan Union Oncol</source>. (<year>2019</year>) <volume>24</volume>:<page-range>701&#x02013;8</page-range>.</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Huangfu</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>PTEN/AKT/mTOR signaling mediates anticancer effects of epigallocatechin-3-gallate in ovarian cancer</article-title>. <source>Oncol Rep</source>. (<year>2020</year>) <volume>43</volume>:<page-range>1885&#x02013;96</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3892/or.2020.7571</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arnesano</surname><given-names>F</given-names></name><name><surname>Natile</surname><given-names>G</given-names></name></person-group>. <article-title>Interference between copper transport systems and platinum drugs</article-title>. <source>Semin Cancer Biol</source>. (<year>2021</year>) <volume>76</volume>:<page-range>173&#x02013;88</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.semcancer.2021.05.023</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zahid</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake</article-title>. <source>Mol carcinogenesis</source>. (<year>2019</year>) <volume>58</volume>:<fpage>794</fpage>&#x02013;<lpage>807</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/mc.22971</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lukanovi&#x00107;</surname><given-names>D</given-names></name><name><surname>Herzog</surname><given-names>M</given-names></name><name><surname>Kobal</surname><given-names>B</given-names></name><name><surname>&#x0010c;erne</surname><given-names>K</given-names></name></person-group>. <article-title>The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer</article-title>. <source>Biomedicine pharmacotherapy = Biomedecine pharmacotherapie</source>. (<year>2020</year>) <volume>129</volume>:<elocation-id>110401</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.biopha.2020.110401</pub-id>
<pub-id pub-id-type="pmid">32570116</pub-id>
</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bian</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>ATM expression is elevated in established radiation-resistant breast cancer cells and improves DNA repair efficiency</article-title>. <source>Int J Biol Sci</source>. (<year>2020</year>) <volume>16</volume>:<page-range>1096&#x02013;106</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7150/ijbs.41246</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Yeku</surname><given-names>OO</given-names></name><name><surname>Rafiq</surname><given-names>S</given-names></name><name><surname>Purdon</surname><given-names>T</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages</article-title>. <source>Nat Commun</source>. (<year>2020</year>) <volume>11</volume>:<fpage>6298</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-020-20140-0</pub-id>
<pub-id pub-id-type="pmid">33293516</pub-id>
</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khan</surname><given-names>ANH</given-names></name><name><surname>Emmons</surname><given-names>TR</given-names></name><name><surname>Magner</surname><given-names>WJ</given-names></name><name><surname>Alqassim</surname><given-names>E</given-names></name><name><surname>Singel</surname><given-names>KL</given-names></name><name><surname>Ricciuti</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients</article-title>. <source>Cancer immunology immunotherapy: CII</source>. (<year>2022</year>) <volume>71</volume>:<page-range>2355&#x02013;69</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00262-022-03156-x</pub-id>
</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Flores</surname><given-names>L</given-names></name><name><surname>Ngai</surname><given-names>HW</given-names></name><name><surname>Cornejo</surname><given-names>YR</given-names></name><name><surname>Haber</surname><given-names>T</given-names></name><name><surname>McDonald</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Large, anionic liposomes enable targeted intraperitoneal delivery of a TLR 7/8 agonist to repolarize ovarian tumors&#x02019; Microenvironment</article-title>. <source>Bioconjugate Chem</source>. (<year>2021</year>) <volume>32</volume>:<page-range>1581&#x02013;92</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1021/acs.bioconjchem.1c00139</pub-id>
</mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parayath</surname><given-names>NN</given-names></name><name><surname>Gandham</surname><given-names>SK</given-names></name><name><surname>Leslie</surname><given-names>F</given-names></name><name><surname>Amiji</surname><given-names>MM</given-names></name></person-group>. <article-title>Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer</article-title>. <source>Cancer Lett</source>. (<year>2019</year>) <volume>461</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.canlet.2019.07.002</pub-id>
<pub-id pub-id-type="pmid">31288064</pub-id>
</mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Ru</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer</article-title>. <source>J nanobiotechnology</source>. (<year>2022</year>) <volume>20</volume>:<fpage>50</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12951-022-01264-5</pub-id>
<pub-id pub-id-type="pmid">35078498</pub-id>
</mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Reactivation of dysfunctional dendritic cells by a stress-relieving nanosystem resets anti-tumor immune landscape</article-title>. <source>Nano Today</source>. (<year>2022</year>) <volume>43</volume>:<fpage>101416</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.nantod.2022.101416</pub-id>
</mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Development of a dendritic cell/tumor cell fusion cell membrane nano-vaccine for the treatment of ovarian cancer</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>828263</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.828263</pub-id>
<pub-id pub-id-type="pmid">35251013</pub-id>
</mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Long</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>D</given-names></name><name><surname>Yue</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Sonosensitizer nanoplatform-mediated sonodynamic therapy induced immunogenic cell death and tumor immune microenvironment variation</article-title>. <source>Drug delivery</source>. (<year>2022</year>) <volume>29</volume>:<page-range>1164&#x02013;75</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/10717544.2022.2058653</pub-id>
</mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Cancer-erythrocyte hybrid membrane-camouflaged magnetic nanoparticles with enhanced photothermal-immunotherapy for ovarian cancer</article-title>. <source>ACS nano</source>. (<year>2021</year>) <volume>15</volume>:<page-range>19756&#x02013;70</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1021/acsnano.1c07180</pub-id>
</mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ling</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Point-source burst of coordination polymer nanoparticles for tri-modality cancer therapy</article-title>. <source>Biomaterials</source>. (<year>2021</year>) <volume>270</volume>:<elocation-id>120690</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.120690</pub-id>
<pub-id pub-id-type="pmid">33561626</pub-id>
</mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Inamdar</surname><given-names>VV</given-names></name><name><surname>Sigmund</surname><given-names>EC</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Stephan</surname><given-names>SB</given-names></name><name><surname>Watson</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>BiTE secretion from <italic>in situ</italic>-programmed myeloid cells results in tumor-retained pharmacology</article-title>. <source>J Controlled release: Off J Controlled Release Soc</source>. (<year>2022</year>) <volume>342</volume>:<fpage>14</fpage>&#x02013;<lpage>25</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jconrel.2021.12.029</pub-id>
</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Mu</surname><given-names>W</given-names></name><name><surname>Barry</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>A</given-names></name><name><surname>Carpenter</surname><given-names>RL</given-names></name><etal/></person-group>. <article-title>Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway</article-title>. <source>J Exp Clin Cancer research: CR</source>. (<year>2022</year>) <volume>41</volume>:<fpage>41</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13046-022-02244-1</pub-id>
<pub-id pub-id-type="pmid">35086548</pub-id>
</mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suurs</surname><given-names>FV</given-names></name><name><surname>Lorenczewski</surname><given-names>G</given-names></name><name><surname>Bailis</surname><given-names>JM</given-names></name><name><surname>Stienen</surname><given-names>S</given-names></name><name><surname>Friedrich</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues. Journal of nuclear medicine: official publication</article-title>. <source>Soc Nucl Med</source>. (<year>2021</year>) <volume>62(12)</volume>:<page-range>1797&#x02013;804</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2967/jnumed.120.259036</pub-id>
</mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Elechalawar</surname><given-names>CK</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Frickenstein</surname><given-names>AN</given-names></name><name><surname>Asfa</surname><given-names>S</given-names></name><name><surname>Fung</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>Disabling partners in crime: Gold nanoparticles disrupt multicellular communications within the tumor microenvironment to inhibit ovarian tumor aggressiveness</article-title>. <source>Materials Today (Kidlington England)</source>. (<year>2022</year>) <volume>56</volume>:<fpage>79</fpage>&#x02013;<lpage>95</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.mattod.2022.01.025</pub-id>
<pub-id pub-id-type="pmid">36188120</pub-id>
</mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XF</given-names></name><name><surname>Gurunathan</surname><given-names>S</given-names></name></person-group>. <article-title>Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy</article-title>. <source>Int J nanomedicine</source>. (<year>2016</year>) <volume>11</volume>:<page-range>3655&#x02013;75</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2147/IJN.S111279</pub-id>
</mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yi</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Xing</surname><given-names>J</given-names></name><name><surname>Gedanken</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Micelle encapsulation zinc-doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair</article-title>. <source>Bioengineering Trans Med</source>. (<year>2023</year>) <volume>8</volume>:<fpage>e10507</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/btm2.10507</pub-id>
</mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qiu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Engineering chemotherapeutic-augmented calcium phosphate nanoparticles for treatment of intraperitoneal disseminated ovarian cancer</article-title>. <source>ACS Appl materials interfaces</source>. (<year>2022</year>) <volume>14</volume>:<page-range>21954&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1021/acsami.2c02552</pub-id>
</mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pisano</surname><given-names>S</given-names></name><name><surname>Pierini</surname><given-names>I</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Gazze</surname><given-names>A</given-names></name><name><surname>Francis</surname><given-names>LW</given-names></name><name><surname>Gonzalez</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Immune (Cell) derived exosome mimetics (IDEM) as a treatment for ovarian cancer</article-title>. <source>Front Cell Dev Biol</source>. (<year>2020</year>) <volume>8</volume>:<elocation-id>553576</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcell.2020.553576</pub-id>
<pub-id pub-id-type="pmid">33042993</pub-id>
</mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Darzynkiewicz</surname><given-names>Z</given-names></name><name><surname>Traganos</surname><given-names>F</given-names></name><name><surname>Wlodkowic</surname><given-names>D</given-names></name></person-group>. <article-title>Impaired DNA damage response&#x02013;an Achilles&#x02019; heel sensitizing cancer to chemotherapy and radiotherapy</article-title>. <source>Eur J Pharmacol</source>. (<year>2009</year>) <volume>625</volume>:<page-range>143&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ejphar.2009.05.032</pub-id>
</mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Joudeh</surname><given-names>N</given-names></name><name><surname>Linke</surname><given-names>D</given-names></name></person-group>. <article-title>Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists</article-title>. <source>J nanobiotechnology</source>. (<year>2022</year>) <volume>20</volume>:<fpage>262</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12951-022-01477-8</pub-id>
<pub-id pub-id-type="pmid">35672712</pub-id>
</mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vasan</surname><given-names>N</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name></person-group>. <article-title>A view on drug resistance in cancer</article-title>. <source>Nature</source>. (<year>2019</year>) <volume>575</volume>:<fpage>299</fpage>&#x02013;<lpage>309</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-019-1730-1</pub-id>
<pub-id pub-id-type="pmid">31723286</pub-id>
</mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy</article-title>. <source>J nanobiotechnology</source>. (<year>2024</year>) <volume>22</volume>:<fpage>737</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12951-024-03005-2</pub-id>
<pub-id pub-id-type="pmid">39605063</pub-id>
</mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ocansey</surname><given-names>DKW</given-names></name><name><surname>Qian</surname><given-names>F</given-names></name><name><surname>Cai</surname><given-names>P</given-names></name><name><surname>Ocansey</surname><given-names>S</given-names></name><name><surname>Amoah</surname><given-names>S</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Current evidence and therapeutic implication of PANoptosis in cancer</article-title>. <source>Theranostics</source>. (<year>2024</year>) <volume>14</volume>:<page-range>640&#x02013;61</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7150/thno.91814</pub-id>
</mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name></person-group>. <article-title>The emerging role of PANoptosis in cancer treatment</article-title>. <source>Biomedicine pharmacotherapy = Biomedecine pharmacotherapie</source>. (<year>2023</year>) <volume>168</volume>:<elocation-id>115696</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.biopha.2023.115696</pub-id>
<pub-id pub-id-type="pmid">37837884</pub-id>
</mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peralta</surname><given-names>RM</given-names></name><name><surname>Xie</surname><given-names>B</given-names></name><name><surname>Lontos</surname><given-names>K</given-names></name><name><surname>Nieves-Rosado</surname><given-names>H</given-names></name><name><surname>Spahr</surname><given-names>K</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism</article-title>. <source>Nat Immunol</source>. (<year>2024</year>) <volume>25</volume>:<page-range>2297&#x02013;307</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41590-024-01999-3</pub-id>
</mixed-citation></ref></ref-list><glossary><title>Glossary</title><def-list><def-item><term>AOC</term><def><p>Advanced ovarian cancer</p></def></def-item><def-item><term>TME</term><def><p>tumor microenvironment</p></def></def-item><def-item><term>DDR</term><def><p>DNA damage response</p></def></def-item><def-item><term>EMT</term><def><p>epithelial-mesenchymal transition</p></def></def-item><def-item><term>NPs</term><def><p>nanoparticles</p></def></def-item><def-item><term>ECM</term><def><p>extracellular matrix</p></def></def-item><def-item><term>ICCs</term><def><p>immunocompetent cells</p></def></def-item><def-item><term>DCs</term><def><p>dendritic cells</p></def></def-item><def-item><term>NK cells</term><def><p>natural killer cells</p></def></def-item><def-item><term>TAMs</term><def><p>tumor-associated macrophages</p></def></def-item><def-item><term>Tregs</term><def><p>regulatory T cells</p></def></def-item><def-item><term>MDSCs</term><def><p>myeloid-derived suppressor cells</p></def></def-item><def-item><term>PD-L1</term><def><p>Programmed cell death ligand 1</p></def></def-item><def-item><term>STAT3</term><def><p>signal transducer and activator of transcription 3</p></def></def-item><def-item><term>JAK</term><def><p>Janus kinase</p></def></def-item><def-item><term>TI-DCs</term><def><p>Tumor-infiltrating dendritic cells</p></def></def-item><def-item><term>ROS</term><def><p>reactive oxygen species</p></def></def-item><def-item><term>4-HNE</term><def><p>4-hydroxynonenal</p></def></def-item><def-item><term>ER</term><def><p>endoplasmic reticulum</p></def></def-item><def-item><term>IRE1&#x003b1;</term><def><p>inositol-requiring kinase 1&#x003b1;</p></def></def-item><def-item><term>XBP1</term><def><p>X-box binding protein 1</p></def></def-item><def-item><term>FAO</term><def><p>fatty acid oxidation</p></def></def-item><def-item><term>IL-10</term><def><p>interleukin 10</p></def></def-item><def-item><term>TGF-&#x003b2;</term><def><p>transforming growth factor &#x003b2;</p></def></def-item><def-item><term>TCF/LEF</term><def><p>T cell factor/lymphoid enhancer factor</p></def></def-item><def-item><term>CXCL2</term><def><p>CXC motif chemokine ligand 2</p></def></def-item><def-item><term>TLRs</term><def><p>Toll-like receptors</p></def></def-item><def-item><term>TNFRs</term><def><p>tumor necrosis factor receptors</p></def></def-item><def-item><term>CTLs</term><def><p>cytotoxic T lymphocytes</p></def></def-item><def-item><term>RIPK1</term><def><p>receptor-interacting serine/threonine-protein kinase 1</p></def></def-item><def-item><term>IKK</term><def><p>IkB kinase</p></def></def-item><def-item><term>CTLA-4</term><def><p>Cytotoxic T lymphocyte associate protein-4</p></def></def-item><def-item><term>Mcl-1</term><def><p>myeloid leukemia factor 1</p></def></def-item><def-item><term>MCT</term><def><p>monocarboxylate transporter</p></def></def-item><def-item><term>PDK1</term><def><p>pyruvate dehydrogenase kinase 1</p></def></def-item><def-item><term>PIP3</term><def><p>phosphatidylinositol triphosphate</p></def></def-item><def-item><term>GSK3b</term><def><p>glycogen synthase kinase 3b</p></def></def-item><def-item><term>p70S6K</term><def><p>p70 ribosomal protein S6 kinase</p></def></def-item><def-item><term>CTR1</term><def><p>copper transporter 1</p></def></def-item><def-item><term>UBR5</term><def><p>Ubiquitin protein ligase E3 component n-recognin 5</p></def></def-item><def-item><term>MSV</term><def><p>multistage vector</p></def></def-item><def-item><term>VSSP</term><def><p>Very small size particles</p></def></def-item><def-item><term>NAcGM3</term><def><p>N-acetylneuramic acid</p></def></def-item><def-item><term>OMV</term><def><p>outer membrane vesicles</p></def></def-item><def-item><term>RSQ</term><def><p>Resiquimod</p></def></def-item><def-item><term>KT-NE</term><def><p>KIRA6 loaded &#x003b1;-Tocopherol nanoemulsion</p></def></def-item><def-item><term>PLGA</term><def><p>poly lactic-co-glycolic acid</p></def></def-item><def-item><term>CpG-ODN</term><def><p>CpG-oligodeoxynucleotide</p></def></def-item><def-item><term>PFH</term><def><p>perfluorohexane</p></def></def-item><def-item><term>IRM</term><def><p>hybrid biomimetic coating</p></def></def-item><def-item><term>IVT</term><def><p>
<italic>in vitro</italic>-transcribed</p></def></def-item><def-item><term>MVB</term><def><p>multivesicular body</p></def></def-item><def-item><term>GNP</term><def><p>Gold nanoparticle</p></def></def-item><def-item><term>MEF2D</term><def><p>Myocyte Enhancer Factor 2D</p></def></def-item><def-item><term>Sal</term><def><p>salinomycin</p></def></def-item><def-item><term>TP</term><def><p>triptolide</p></def></def-item><def-item><term>MEnZn-CuO</term><def><p>Micelle Encapsulation Zinc-doped copper oxide</p></def></def-item><def-item><term>RGD</term><def><p>Arg-Gly-Asp</p></def></def-item><def-item><term>DOX</term><def><p>doxorubicin</p></def></def-item><def-item><term>IDEM</term><def><p>immune-derived exosome simulator.</p></def></def-item></def-list></glossary></back></article>